CN1806587A - Immunity-regulating milk and preparation method thereof - Google Patents
Immunity-regulating milk and preparation method thereof Download PDFInfo
- Publication number
- CN1806587A CN1806587A CN 200610002649 CN200610002649A CN1806587A CN 1806587 A CN1806587 A CN 1806587A CN 200610002649 CN200610002649 CN 200610002649 CN 200610002649 A CN200610002649 A CN 200610002649A CN 1806587 A CN1806587 A CN 1806587A
- Authority
- CN
- China
- Prior art keywords
- milk
- arginine
- group
- mouse
- immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of combination milk and its preparing process, wherein the milk is prepared by adding L-arginine into conventional milk and through homogeneity process. The milk has the functions of adjusting body immunity.
Description
Invention field
The present invention relates to a kind of milk and preparation technology thereof, particularly a kind of milk and preparation technology thereof who regulates immunity of organisms.
Background technology
Arginine has the important physical function at human body.Biochemical research has proved the important function of arginine in the urea cycle metabolism for a long time.Therefore, arginine is used as a kind of medicine of ammonia poisoning of removing for a long time in wide clinical application.The research of nutrition has proved that also arginine is a kind of condition essential amino acid.When being in body internal protein catabolism such as starvation, protein excess intake, wound, puberal growth stage when human body and strengthening, arginic requirement will increase greatly.On the meaning of nutrition, arginine has good reproduction trophic function, has important trophism in the growth of reproduction cell and sperm forming process.Studies have shown that recently, arginine are synthetic nitric oxide production substrates, and people have progressively found arginic many immunological regulations and cardiovascular biologically active thus.Experimental study shows, the formation that edible for a long time arginine can the prevention of arterial sclerosis.Human body physiologicals such as wound (operation, accidental wound, burn), high temperature stress and many psychogenics stress situation under arginine for the immunologic hypofunction that causes in response to swashing significant prevention and restitution are arranged.Research is proof also, and arginine can improve the immune surveillance function of body, regulates the functional relationship of suppressor T lymphocyte, killer T cell and helper T lymphocyte, thereby has unique effect for the immunoprophylaxis and the treatment of tumour.
Studies have shown that of drug preparation technique has a lot of medicines or bioactivator to make emulsion through emulsifying agent and emulsifying process, and its bioavilability can improve greatly.In traditional knowledge, such emulsifying process usually is to realize by adding various natural or synthetic emulsifying agents.
Milk is one of the most frequently used food of the most nutritious and people, is again the best natural emulsion simultaneously, can be used as desirable emulsion of many nutriments, medicine and other bioactivator or fortification carrier.Though the human milk that has developed many enhanced nutrients is for example strengthened calcium, vitamin A, D, Taurine etc., relevantly in milk, strengthen arginic research and yet there are no research report.
Summary of the invention
The object of the invention is to provide a kind of L-arginine formula combination milk and preparation method thereof, and another purpose of the present invention is to provide the new purposes of this formula combination milk.
The present invention seeks to be achieved through the following technical solutions:
L-arginine milk of the present invention is to be that 0.5-20g is formulated by L-arginine content in the 100ml milk; The preferred 1g of L-arginine content, 5g, 10g, 20g in the 100ml milk.
Formula combination milk preferred for preparation method of the present invention is as follows:
Getting ordinary milk, is 20% (g/ml) by L-arginine content in milk, adds the L-arginine in milk, and makes through high-pressure homogeneous processes.
L-arginine milk has and strengthens immunologic function and blood tonification effect preferably.High temperature stress cause mouse thymus, spleen atrophy, lose weight; but can alleviate and alleviate the acute atrophy of thymus gland, spleen behind the additional arginine; improve phagocytic function; the effect of protection thymocyte structural intergrity, and just can play protective effect to immune organ at finite concentration.
No matter arginine milk is at normal temperature, still behind heat stress, can both improve expression rate and the activation thymocyte [Ca of lymphocyte ConA SI, IL-2 content, IL-2R
2+], and concentration best results when reaching 1.5mg/g.Under the high temperature stressed condition, replenish the integrality that L-arginine milk can be protected the thymocyte structure.
In milk, strengthen compatibility according to a certain percentage, and be a kind of combination formula milk with remarkable adjusting body's immunity, the single effect that better adjusting immunity of organisms is arranged with arginine of this formula milk through the milk that special process is processed into.Because the milk daily food of drinking that is people, so, L-arginine milk of the present invention can be more convenient, more has biddability ground to be used for the immunologic hypofunction crowd, (for example pestilence is popular, physics and psychological stress, disease and surgical postoperative etc.) needs strengthen the crowd and the rescue of the immunologic function behind immunotherapy of cancer patients and the chemicotherapy of immunologic function under various natural, physiology and pathological conditions.Milk of the present invention can also be made various dairy produces.
Following experimental example is used to further specify but is not limited to the present invention.
Experimental example 1 L-arginine milk of the present invention is to immunologic hypofunction mouse immune organ weight's influence
Get 40 of Kunming mouses, male and female half and half, body weight 20 ± 2g is divided into four groups of blank group (A), model group (B), L-arginine aqueous solution group (C) and L-arginine milk groups (D), 10 every group at random.D group mouse gavages L-arginine milk with 1.5g/kg dosage; C group mouse gavages the equal-volume L-arginine aqueous solution with 1.5g/kg dosage; Model group and blank group mouse all gavage equal-volume physiological saline, once a day, and successive administration 10 days.In administration beginning in the 7th day, D group, C group and B organize mouse all by the amount intraperitoneal injection of cyclophosphamide of 60mg/kg, continuous 4 days; Blank group mouse, is irritated stomach and injects endoxan after 2 hours last day as blank with approach injection equivalent physiological saline, puts to death animal, weigh, cut open rapidly and get thymus gland, spleen tissue, inhale with filter paper and remove the blood of its surface attachment, on precision torsion balance, claim its weight in wet base immediately.The results are shown in Table 1.
Table 1 L-arginine milk is to immunologic hypofunction mouse immune organ weight's influence (x ± SD)
| Group | Number of animals (n) | Dosage (g/kg) | Thymus index (mg/10g) | Spleen index (mg/10g) |
| A B C D | 10 10 10 10 | NS NS 1.5 | 21.68±2.46 13.02±1.31 * 15.22±1.36 # 23.31±2.01 ##Δ | 51.14±6.14 30.92±4.60 * 37.03±4.55 # 48.01±5.53 ##Δ |
Compare with the blank group,
*P＜0.01;
Compare with model group,
*P＜0.05,
*P＜0.01;
Compare Δ P＜0.05 with aqueous solution group
The result shows that model group compares with blank group, and its thymus index and spleen index obviously reduce (P＜0.01), and the modeling success is described.
Compare with model group, the thymus index and the spleen index of L-arginine aqueous solution group and L-arginine milk group (P＜0.05 that obviously raises, P＜0.01), illustrates that two kinds of solution improve significantly for immune organ weight and the immunologic function decline tool thereof that endoxan causes.
Compare with L-arginine aqueous solution group, L-arginine milk group thymus index and spleen index raise more obvious (P＜0.05), illustrates that the immune organ weight that L-arginine milk causes for endoxan and the improvement effect of immunologic function decline thereof are better than using merely the L-arginine.
Experimental result shows: endoxan can cause immune function of mice low, and the immune organ weight index is descended.L-arginine milk can the antagonism endoxan immunosuppressive action, protection mouse thymus and spleen are avoided its infringement, illustrates that arginine milk of the present invention has the effect of enhancing immunologic function.
Experimental example 2 L-arginine milk of the present invention are to the influence of model of blood dificiency mouse red blood cell and hemoglobin
Get Kunming mouse, male and female half and half, body weight 20 ± 2g is divided into model group, L-arginine aqueous solution group and L-arginine milk group, 10 every group at random.Measure each mouse administration proerythrocyte (RBC) and hemoglobin (Hb) value earlier, after the afterbody depletion method causes losing blood property model of blood dificiency (RBC, Hb all are starkly lower than normal value) then, L-arginine aqueous solution group gavages the L-arginine aqueous solution with 1.5g/kg dosage, L-arginine milk group then gavages isopyknic L-arginine milk every day, model group gavages equal-volume physiological saline, is once a day.Gavaged 12 days continuously.After the last administration 2 hours, RBC and Hb value are surveyed in the afterbody blood sampling.The results are shown in Table 2.
Table 2 L-arginine milk is to the influence of model of blood dificiency mouse red blood cell and hemoglobin (x ± SD)
| Group | Number of animals (n) | Dosage (g/kg) | RBC (ten thousand/the mm that rises in value 3) | Hb rise in value (g%) |
| Model group L-arginine aqueous solution group L-arginine milk group | 10 10 10 | NS 1.5 1.5 | 246.88±38.86 296.79±37.78* 351.51±36.86**Δ | 2.72±0.44 3.48±0.41* 4.15±0.51**Δ |
Compare with model group,
*P＜0.05,
*P＜0.01;
Compare Δ P＜0.05 with aqueous solution group
Experimental result shows: takes deficiency of blood mouse RBC and the Hb value of L-arginine milk after 12 days and is significantly higher than model group (P＜0.01) and L-arginine aqueous solution group, illustrate that L-arginine formula combination milk has blood tonification effect preferably,
Experimental example 3 high temperature stress descend to replenish L-arginine milk to effect of immunologic function
(1) animal used as test and grouping
Select for use 6～8 ages in week 105 of male BALB/C mices, animal is bought the back back and adapts to three days down in room temperature (25 ± 1 ℃, relative humidity 50%), freely ingests and drinks running water.105 mouse are divided into 3 groups at random, and the A group is control group: give aquae destillata; B group: press L-arginine 1.5g/kg, irritate stomach with the L-arginine aqueous solution; C group: press arginine 1.5g/kg, irritate stomach with 20%L-arginine milk;
(2) high temperature stress method
Every group of 35 mouse are further divided into 7 groups, 5 of every groups (being that normal temperature contrast, heat stress are handled back 0,2,4,8,12,24h).The high temperature storehouse is not gone in the normal temperature contrast, and all the other 6 groups all go into the high temperature storehouse and accept heat stress.Control group and each processed group are irritated stomach and are put into animal high temperature experiment storehouse after 14 days and carry out heat stress and handle, and parameter is that dry-bulb temperature is (41 ± 0.5) ℃, and relative humidity is 65%, and the heat stress time is 120min.
(3) experimental result
1, L-arginine milk is to the influence of heat-stressed mice thymus index and index and spleen index
Body weight (g) behind thymus gland or index and spleen index=thymus gland or spleen quality (the g)/mouse heat stress
Table 3 is respectively organized mouse thymus index variation (x ± SD)
| Grouping | A | B | C |
| Normal temperature 0h 2h 4h 8h 12h 24h | 0.48±0.03 0.20±0.03 0.18±0.02 0.13±0.01 0.17±0.01 0.26±0.02 0.25±0.02 | 0.72±0.04 0.30±0.02 0.22±0.01 0.21±0.03 0.25±0.02 0.37±0.01 0.34±0.02 | 0.82±0.04 0.63±0.04 0.47±0.02 0.31±0.04 0.32±0.02 0.59±0.05 0.61±0.02 |
The variation of table 4 experiment mice index and spleen index (x ± SD)
| Grouping | A | B | C |
| Normal temperature 0h 2h 4h 8h 12h 24h | 0.71±0.05 0.30±0.05 0.27±0.03 0.20±0.02 0.25±0.02 0.39±0.03 0.38±0.03 | 1.08±0.06 0.46±0.03 0.34±0.02 0.32±0.05 0.37±0.03 0.55±0.02 0.51±0.03 | 1.23±0.02 0.95±0.06 0.71±0.04 0.47±0.06 0.48±0.03 0.89±0.07 0.91±0.04 |
Experimental result shows: the thymus index and the index and spleen index of not replenishing the arginic heat stress group of L-mouse all significantly are lower than corresponding normal temperature control group; under the heat stress condition, all be significantly higher than its aqueous solution group and replenish L-arginine milk group mouse two indexes; prompting is compared with the arginic aqueous solution of L-, L-arginine milk have immune organs such as better protection spleen and thymus gland high temperature stress the time the effect of acute atrophy.
2, L-arginine milk is to the influence of heat-stressed mice lymphocyte proliferation activity
The mouse lymphocyte proliferation activity is represented with the ConA SI, ConA SI=experimental port absorbance (OD value)/control wells absorbance (OD value), and experimental result sees Table 5.
The variation of table 5 experiment mice lymphocyte proliferation activity (ConA SI) (x ± SD)
| Grouping | A | B | C |
| Normal temperature 0h 2h 4h 8h 12h 24h | 1.05±0.01 1.01±0.00 1.01±0.00 1.00±0.00 1.00±0.00 1.01±0.01 1.04±0.03 | 1.28±0.05 1.20±0.04 1.16±0.02 1.12±0.01 1.12±0.02 1.26±0.04 1.28±0.02 | 1.45±0.04 1.35±0.01 1.29±0.02 1.22±0.03 1.22±0.01 1.42±0.03 1.45±0.03 |
Experimental result shows: compare with L-arginine aqueous solution group, milk group experiment mice lymphocyte under stronger stimulation high temperature stressed condition in L-arginine assembly side has increment active.
3, L-arginine milk is to the influence of heat-stressed mice thymocyte IL-2 content
L-arginine milk sees Table 6 to the experimental result of the content influence of the thymocyte IL-2 of heat-stressed mice activation.
The variation of each experimental mice IL-2 mass concentration of table 6 (x ± SD) (ng/l)
| Grouping | A | B | C |
| Normal temperature 0h 2h 4h 8h 12h 24h | 1926.4±94.2 1585.2±71.6 1321.0±59.6 1358.8±61.3 1359.9±51.2 1906.8±85.0 1931.0±95.8 | 2683.4±23.3 2236.1±56.1 1863.4±30.0 1916.7±33.8 1983.4±83.6 2604.1±65.5 2647.7±57.4 | 4162.7±75.5 3489.6±33.3 2908.0±55.1 2991.1±66.2 2944.1±54.8 4135.4±99.4 4211.3±75.8 |
Experimental result shows: compare with the L-arginine aqueous solution, L-arginine milk has the effect of better raising experiment mice thymocyte IL-2 content.
4, L-arginine milk is to the influence of the thymocyte IL-2R expression of heat-stressed mice activation
Thymocyte IL-2R to activation expresses, and the result represents with the percentage that the IL-2R positive cell number accounts for the cell number of being surveyed (5000 cells).The results are shown in Table 7.
The variation of each experimental mice of the table 7 activation thymocyte IL-2R expression rate (% of x ± SD)
| Grouping | A | B | C |
| Normal temperature group 0h 2h 4h 8h 12h 24h | 27.34±2.33 22.30±2.52 19.48±2.32 17.18±2.00 17.44±2.35 22.54±2.36 23.58±2.32 | 45.40±2.15 41.66±3.49 40.70±2.62 36.94±2.85 36.52±2.79 40.66±3.17 45.68±4.16 | 59.16±1.90 50.92±3.67 47.58±2.52 42.62±2.31 41.80±2.88 47.60±1.78 58.68±2.05 |
Experimental result shows: compare with the L-arginine aqueous solution, L-arginine milk has the effect that experiment mice thymocyte IL-2R expresses under the better promotion high temperature stressed condition.
5, L-arginine milk is to the influence of thymocyte cytosolic free calcium ion concentration
The thymocyte slurry free calcium ions [Ca of activation
2+] represent that with fluorescence intensity measurement result sees Table 8.
Table 8 is respectively organized cytoplasm [Ca
2+] variation (x ± SD) of fluorescence intensity
| Grouping | A | B | C |
| Normal temperature group normal temperature group 0h 2h 4h 8h 12h 24h | 27.34±2.33 161.04±2.92 115.26±2.31 116.40±1.59 113.42±5.26 119.10±4.61 146.43±3.96 160.60±2.94 | 45.40±2.15 179.9±14.35 143.20±10.9 145.41±8.05 145.40±14.3 158.50±15.4 171.81±3.90 178.03±7.17 | 59.16±1.90 198.64±2.59 183.36±5.83 179.35±2.00 177.26±4.16 180.76±5.57 198.60±5.16 201.16±3.46 |
Experimental result shows: compare with L-arginine aqueous solution group, L-arginine milk group has better activation thymocyte [Ca
2+] effect.Therefore, can think under the high temperature stressed condition, replenish the integrality that L-arginine milk can be protected the thymocyte structure.
Following embodiment all can realize the described effect of above-mentioned experimental example.
Embodiment 1: get milk 100ml, add 1g L-arginine in milk, through high-pressure homogeneous processes, make the L-arginine formula combination milk of 1% (g/ml) concentration.
Embodiment 2: get milk 100ml, add 5g L-arginine in milk, through high-pressure homogeneous processes, make the L-arginine formula combination milk of 5% (g/ml) concentration.
Embodiment 3: get milk 100ml, add 10g L-arginine in milk, through high-pressure homogeneous processes, make the L-arginine formula combination milk of 10% (g/ml) concentration.
Embodiment 4: get milk 100ml, add 20g L-arginine in milk, through high-pressure homogeneous processes, make the L-arginine formula combination milk of 20% (g/ml) concentration.
Claims (9)
1, a kind of milk of regulating immunity of organisms is characterized in that this milk is is that 0.5-20g is formulated by L-arginine content in the 100ml milk.
2, milk as claimed in claim 1 is characterized in that this milk is is that 1g is formulated by the L-arginine content in the 100ml milk.
3, milk as claimed in claim 1 is characterized in that this milk is is that 5g is formulated by L-arginine content in the 100ml milk.
4, milk as claimed in claim 1 is characterized in that this milk is is that 10g is formulated by L-arginine content in the 100ml milk.
5, milk as claimed in claim 1 is characterized in that this milk is is that 20g is formulated by L-arginine content in the 100ml milk.
6, as the preparation method of claim 1,2,3,4 or 5 described milk, it is characterized in that this method may further comprise the steps: get ordinary milk, press the concentration of 0.5-20% and in milk, add the L-arginine, and make through high-pressure homogeneous processes.
7, the preparation method of milk as claimed in claim 6 is characterized in that this method may further comprise the steps: get ordinary milk, add the L-arginine by 10% concentration in milk, and make through high-pressure homogeneous processes.
8, has the effect of regulating body's immunity as claim 1,2,3,4 or 5 described formula combination milk.
9, has application in the dairy produce of regulating body's immunity as claim 1,2,3,4 or 5 described formula combination milk in preparation.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610002649 CN1806587A (en) | 2006-01-26 | 2006-01-26 | Immunity-regulating milk and preparation method thereof |
| CNB2006101702990A CN100502672C (en) | 2006-01-26 | 2006-12-27 | Milk for regulating organism immunity and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610002649 CN1806587A (en) | 2006-01-26 | 2006-01-26 | Immunity-regulating milk and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1806587A true CN1806587A (en) | 2006-07-26 |
Family
ID=36838814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610002649 Pending CN1806587A (en) | 2006-01-26 | 2006-01-26 | Immunity-regulating milk and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1806587A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429032A (en) * | 2011-11-14 | 2012-05-02 | 江苏星驰生物科技有限公司 | Cow fore milk formula powder for postoperative rehabilitation |
| CN103960366A (en) * | 2014-04-30 | 2014-08-06 | 程礼华 | Nutrient enrichment type flavored walnut milk and preparation device and preparation method thereof |
-
2006
- 2006-01-26 CN CN 200610002649 patent/CN1806587A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429032A (en) * | 2011-11-14 | 2012-05-02 | 江苏星驰生物科技有限公司 | Cow fore milk formula powder for postoperative rehabilitation |
| CN103960366A (en) * | 2014-04-30 | 2014-08-06 | 程礼华 | Nutrient enrichment type flavored walnut milk and preparation device and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Namba | Maitake D-fraction: healing and preventive potential for cancer | |
| CN1709133A (en) | Selenium-rich probiotics foder additive production method and its product | |
| CN1868302A (en) | Chinese herb medicine additive for chicken feed | |
| CN102630853A (en) | Plant polysaccharose additive premix feed for broiler chicken | |
| CN1903232A (en) | Moringaceae powder nutrition food and method for preparing the same | |
| CN103283847A (en) | Multi-nutritional protein | |
| CN104432107A (en) | Nutritious food for promoting postoperative recovery and application thereof | |
| CN103083510A (en) | Chinese medicinal oral liquid for improving poultry immune function and its preparation method | |
| CN1833661A (en) | Spirulina chewing tablets and prepn. thereof | |
| CN1872338A (en) | Chewing tablet for discharging lead, and preparation method | |
| CN1806587A (en) | Immunity-regulating milk and preparation method thereof | |
| CN102783568B (en) | Feed additive | |
| CN109691597B (en) | Intestinal mitochondria function protective agent for relieving heat stress of broiler chickens | |
| US20110065629A1 (en) | Enteral nutrient | |
| CN106135878A (en) | Jilin Radix Ginseng oligopeptide purposes in preparation improves the food with sexual function improving or health food | |
| CN100502672C (en) | Milk for regulating organism immunity and its preparation | |
| CN105998373A (en) | Health-caring oral liquid for treating hepatitis and preparation method thereof | |
| CN112891360A (en) | New application of deoxyrhaponticin | |
| CN112891363A (en) | New use of New Zealand Vitexin 2 and New Zealand Vitexin 3 | |
| CN1259082C (en) | Medicine for treating respiratory system diseases | |
| CN1135933C (en) | Multifunctional nutritive liquid and its producing method | |
| CN103656320A (en) | Oral compound traditional Chinese medicine preparation for preventing poultry chill cold and flu | |
| CN1389265A (en) | Composite Chinese medicine with health care function | |
| CN107568441A (en) | A kind of pregnancy period scorpion nutrient fodder and preparation method thereof | |
| CN106798158B (en) | Chinese herbal medicine additive compound premix for laying hens and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |